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Scabies, a parasitic skin infestation by the burrowing “itch” mite Sarcoptes scabiei, causes significant health
problems for children and adults worldwide. Crusted scabies is a particularly severe form of scabies in which
mites multiply into the millions, causing extensive skin crusting. The symptoms and signs of scabies suggest
host immunity to the scabies mite, but the specific resistant response in humans remains largely uncharac-
terized. We used 4 scabies mite recombinant proteins with sequence homology to extensively studied house dust
mite allergens to investigate a differential immune response between ordinary scabies and the debilitating
crusted form of the disease. Subjects with either disease form showed serum IgE against recombinant S. scabiei
cysteine and serine proteases and apolipoprotein, whereas naive subjects showed minimal IgE reactivity.
Significantly (P < 0.05) greater serum IgE and IgG4 binding to mite apolipoprotein occurred in subjects with
crusted scabies than in those with ordinary scabies. Both subject groups showed strong proliferative responses
(peripheral blood mononuclear cells) to the scabies antigens, but the crusted scabies group showed increased
secretion of the Th2 cytokines interleukin 5 (IL-5) and IL-13 and decreased Th1 cytokine gamma interferon
(IFN-) in response to the active cysteine protease. These data confirm that a nonprotective allergic response
occurs in the crusted disease form and demonstrate that clinical severity is associated with differences in the
type and magnitude of the antibody and cellular responses to scabies proteins. A quantitative IgE inhibition
assay identified IgE immunoreactivity of scabies mite antigens distinct from that of house dust mite antigens,
which is potentially important for specific scabies diagnosis and therapy.
Scabies is a disease of the skin caused by the burrowing
“itch” mite Sarcoptes scabiei. The predominant disease mani-
festations are mediated through inflammatory and allergic-like
reactions to mite products, leading to intensely pruritic skin
lesions. A spectrum of disease is recognized, from the more
common ordinary scabies (OS), with an average infestation of
10 to 15 mites per person, to a rare and severely debilitating
form of the disease termed crusted (Norwegian) scabies (CS).
In this form, mite infestations can number in the millions, and
hyperkeratotic skin crusts develop (41, 50). Due to the extreme
burden of mites, CS is considerably more infectious, and in-
fectivity persists far longer, as eradicating mites from heavily
crusted skin is extremely difficult.
Crusted scabies is an important public health problem, not
only for the individuals concerned, but also for their families
and communities, in which sufferers may act as “core transmit-
ters” who continue to reinfect others. In many remote Aborig-
inal communities in northern Australia, scabies prevalence is
high: up to 65% in children, with first presentation peaking at
2 months of age (13).
Adult female mites reside in burrows within the stratum
granulosum of the epidermis. The clinical rash and itch present
as papules or vesicles that may contain individual mites, eggs,
egg cases, mite fecal pellets, and debris present in the burrow.
A secondary, more generalized papular immune response also
occurs. The associated underlying inflammatory response var-
ies in intensity, with combinations of lymphocytes, histiocytes,
and polymorphonuclear leukocytes (10, 47). Due to difficulties
in isolating sarcoptic mites on the host in OS and to the clinical
symptoms imitating those of other skin diseases, scabies is a
challenging disease to diagnose (48). To date, limited investi-
gations of humoral immunity to the scabies mite (SM) in pa-
tients have yielded contradictory results and have used scabi-
etic extracts from other hosts, such as dogs (37). Interpretation
of these studies is complex, as scabies mites are highly host
specific and generally produce only a transient, self-limiting
reaction in the nonpermissive host.
In Darwin, Northern Territory, Australia, patients with CS
were noted to have extremely high levels of total IgE and IgG
in serum (41). Western blotting with plasma from these pa-
tients demonstrated that 6 of 7 individuals had strong IgE
binding to S. scabiei var. canis protein extracts (2). Immuno-
chemical studies have previously demonstrated that sera from
rabbits infested with S. scabiei var. canis bind to house dust
mite (HDM) extracts and, conversely, that sera from rabbits
immunized with HDM extract bind with S. scabiei var. canis
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whole-mite protein extract (4–6, 18, 20, 36). Allergens from
HDMs are recognized as major causes of allergic respiratory
disease in humans (17, 43). As SMs and HDMs are phyloge-
netically related arthropods with similar nutritional require-
ments, it is not surprising that these mites or their excreta have
homologous allergens. However, it is likely that only a few of
these allergens are cross-reactive. For example, Der p 5 from
the HDM Dermatophagoides pteronyssinus and Blo t 5 from the
storage mite Blomia tropicalis have been studied extensively,
and although they have 43% amino acid identity, they are not
IgE cross-reactive (31). The identities of the specific cross-
reactive molecules between S. scabiei and D. pteronyssinus re-
main undefined but may be glycan related (33).
The recent development of S. scabiei cDNA libraries and
expressed sequence tag (EST) databases (21, 29) allows more
precise characterization of the specific antigens responsible for
the immune reactions to the SM. The cDNAs encoding S.
scabiei var. hominis cysteine proteases (27), serine proteases
(26), glutathione S-transferase (GST) (16), and apolipoprotein
(25) show homology to the D. pteronyssinus HDM group 1, 3,
8, and 14 allergens, respectively (43). As with HDMs, the
availability of recombinant proteins and identification of key
immunoreactive allergens for the SM would facilitate develop-
ment of refined diagnosis and potential immunotherapy. Thus,
more effective control of mite infestations at both an individual
and a community level may be possible. We report here the
characterization of specific antibody binding profiles and cel-
lular immune responses of subjects with clinical scabies by
using purified S. scabiei var. hominis recombinant proteins.
Quantitative IgE inhibition analysis of cross-reactivity with
HDM allergens identified IgE epitopes of scabies mite pro-
teins distinct from HDM epitopes, a prerequisite for using
purified allergens in scabies diagnosis and therapy.
MATERIALS AND METHODS
Study groups. Blood samples were collected from people living in both remote
and urban regions of Australia. The donors included a total of 82 indigenous and
nonindigenous subjects (33 male and 49 female; mean age, 45 years) from
northern Australia and 13 subjects attending the Allergy Clinic at the Alfred
Hospital, Melbourne (Victoria, Australia). Collection of blood was approved by
the Human Research Ethics Committees of the Northern Territory Department
of Health and Families and the Menzies School of Health Research (approval
number 97/21) and by the Alfred Hospital. Written informed consent was ob-
tained from each donor. Together, the subjects comprised 32 subjects with CS; 24
subjects with OS (endemic infested); 20 naïve, never-exposed subjects without
HDM allergy (nonendemic negative controls; N); and 19 naive, never-exposed
subjects with HDM allergy (nonendemic allergic controls; N-HDM).
Crusted scabies was diagnosed clinically (37) and confirmed microscopically
on the basis of skin scrapings containing more than 5 mites. Demographic
information, risk factors, and immunological parameters are routinely collected
for these patients on admission to the hospital, and only those with no overt
immunosuppression (e.g., malignancies, chemotherapy, HIV, or leprosy) were
included in the study. Due to considerable difficulties in isolating mites from
patients with OS and the lack of a diagnostic blood test for scabies, OS was
diagnosed clinically based on typical lesions and rash. Control (N and N-HDM)
subjects were sourced from the Darwin and Melbourne urban regions, where
scabies is rare. These subjects had no known current scabies or history of scabies.
Collection of blood samples. Heparinized venous blood (50 ml) was centri-
fuged at 645  g for 10 min. Approximately 5 ml of plasma was removed for
serological studies and subsequently replaced with heparinized RPMI 1640
(Gibco Life Technologies, Invitrogen Pty Ltd., Victoria, Australia). Peripheral
blood mononuclear cells (PBMC) were separated by Ficoll-Hypaque (Amer-
sham Pharmacia, GE Healthcare Pty Ltd., NSW, Australia) density gradient
centrifugation using standard methods. The samples were either used immedi-
ately or cryopreserved in liquid nitrogen for later testing.
Antigens: protein sequence and expression. The cDNA was amplified from S.
scabiei var. hominis cDNA libraries (21) by PCR using specific primers. The
primers were designed to amplify the mature forms of an active cysteine protease
molecule, Yv5032CO8 (CO8) (27); an inactive cysteine protease paralogue,
Yv5009FO4 (FO4); an active serine protease, Sar s 3 (GO3) (26); and Ssag1.2,
a 1.2-kb fragment of an S. scabiei apolipoprotein (AF462196) (21) (Table 1). The
PCR products were cloned into the pQE-9 expression vector (Qiagen Ltd.,
Victoria, Australia) in frame with the 6-His tag, and then expressed in the
Escherichia coli strain BL21(pREP4) and purified using Ni-nitrilotriacetic acid
(NTA) agarose (Qiagen Ltd., Victoria, Australia), according to the manufactur-
er’s instructions. The concentration of each protein was determined by Bradford
assay using Bradford reagent (Bio-Rad Laboratories, Regents Park, NSW, Aus-
tralia).
Endotoxin levels in the recombinant proteins were undetectable (3 endo-
toxin units [EU]; QCL-1000 Endotoxin Detection Kit; BioWhittaker, Oslo, Nor-
way). Mitogenicity of the SM recombinant proteins was excluded by culturing
increasing concentrations of the proteins with negative-control PBMC and com-
paring the proliferative responses with that for CS subjects by [3H]thymidine
incorporation. Toxicity was excluded by culturing PBMC with phytohemaggluti-
nin with and without added recombinant protein and comparing the proliferative
responses (data not shown).
Electrophoresis and Western immunoblotting. Purified proteins (0.5 to 1
g/lane), including S. scabiei GST as a control protein (16), were resolved on
12% SDS-PAGE reducing gels for 60 min at 125 V DC, with Benchmark
prestained protein ladders (Invitrogen Pty Ltd., Victoria, Australia) as molecular
mass standards. Gels were stained with Coomassie blue R250 (Sigma-Aldrich,
Sydney, NSW, Australia) or, for Western blotting, transferred to nitrocellulose
membranes (Schleicher and Schuell, Dassel, Germany) for 60 min using standard
methods (9, 44). For Western blots, primary human plasma was diluted 1:50, and
antibody binding was detected using 1:1,000 anti-human IgE alkaline phos-
phatase conjugate (Sigma-Aldrich) developed with BCIP (5-bromo-4-chloro-3-
TABLE 1. Primer sequences for proteases and apolipoprotein
Protein Name Primer sequences (5–3)a Primer restrictionsites Size (aa)
Molecular
mass
(kDa)
GenBank
accession no. Reference(s)
Active cysteine
protease
Yv5032C08 aactgcagAAATTGGGCGAGCTCGATCTG,
cccaagcttTCAAGCTACAGTTTCTTTGC
CCAG
PstI, HindIII 227 25 AY525149 27
Inactive cysteine
protease
Yv5009F04 cgggatccAAACTACCAAAATGGTTCGATC,
ttctgcagTCATTCAAAATCTTCAGGCTC
BamHI, PstI 240 28 AY525155 27
Active serine
protease
Yv7016G03 accggtcgacATTGTCGGCGGTCGTTTAGCT
AAGCC, accgctgcagTTAATTATTTCTAA
GGATATTTTTGATCCATTGG
SalI, PstI 231 26 AY333071 7
Apolipoprotein Ssag1.2 ggggatccTCGAATGTGAAACGAAACAATG,
ggctgcagnnCTGCAAATATTGTCTGA
TAGC
BamHI, PstI 393 46 AF462196 25, 21
a S. scabiei-specific sequence shown in uppercase.
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indolylphosphate)/nitroblue tetrazolium (NBT) substrate (Promega Australia,
Annandale, NSW, Australia).
Immunohistochemistry. Ethics approval for the use of rabbits and mice for
generation of antibodies against SM recombinant antigens was granted by the
Animal Ethics Committee of the Northern Territory University, Darwin, North-
ern Territory, Australia (approval number A99019). Antisera were prepared at
the Veterinary Services Division of the Institute of Medical and Veterinary
Sciences, Gilles Plains, South Australia, using their standard immunization
schedule.
Shed skin tissue highly infested with SMs was obtained from subjects with CS,
and 5-mm3 blocks were fixed in 10% formalin solution. Samples were dehydrated
in ethanol and embedded in paraffin at 60°C, and 6- to 10-m sections were dried
overnight at 34°C. The sections were dewaxed in histolene, rehydrated, and
blocked with 10% goat serum (Sigma-Aldrich)–1% bovine serum albumin (BSA)
(Roche Diagnostic GmbH, Mannheim, Germany)–phosphate-buffered saline
(PBS) for 30 min. Endogenous peroxidase activity was then blocked with 3%
(vol/vol) H2O2 (Fluka Analytical, Sigma-Aldrich, Steinheim, Switzerland)–1%
BSA-PBS for 10 min. After the sections were washed, mouse anti-CO8 or rabbit
anti-Ssag1.2 (1/500 and 1/5,000 in 1% BSA-PBS, respectively) was added for 1 h
at room temperature. After further washing, either Dako EnVision anti-mouse
immunoglobulin (Ig) horseradish peroxidase (HRP)-labeled polymer (Dako Cy-
tomation, Carpinteria, CA), for detection of CO8, or Dako EnVision Dual
Link anti-mouse/anti-rabbit HRP-labeled polymer, for detection of Ssag1.2, was
added for 30 min at room temperature. After another washing, the chromogenic
reaction was conducted using Nova Red (Vector, Burlingame, CA) and previ-
ously described methodology (51). Prebleeds from mice or rabbits used for
raising antibodies were used as negative controls.
For anti-human IgE staining, slides were stained as described above, apart
from an extra incubation step (45 min at 37°C) at the beginning for antigen
retrieval with trypsin (Zymed Laboratories, Invitrogen Corporation, CA). Mouse
anti-human IgE (Zymed Laboratories) was applied (1:500) at room temperature
for 1 h, followed by the secondary antibody, Dako EnVision HRP-labeled
polymer anti-mouse Ig (Dako Cytomation). Chromogenic reactions were then
conducted as described above. Slides were counterstained with Mayer’s hema-
toxylin and bluing solution (0.45% ammonium hydroxide in 70% ethanol).
ELISA. Plasma collected from CS, OS, and N subject groups was tested for
antibody reactivity to CO8, FO4, GO3, and Ssag1.2 by enzyme-linked immu-
nosorbent assay (ELISA) using IgA-, IgG-, IgG1-, IgG4-, and IgE-specific sec-
ondary antibodies. Optimum dilutions of plasma, secondary antibodies, and
tertiary antibodies were first determined by checkerboard titration, using plasma
from subjects with and without scabies and HDM allergy. Antigen-specific assays
were conducted in triplicate and no-antigen background controls in duplicate.
For specific IgE assays, IgG was not adsorbed out prior to plating the plasma.
Briefly, Nunc-Immuno 96-well plates with MaxiSorp (Nalge Nunc Interna-
tional, New York, NY) were coated overnight at 4°C with 50 l per well of
recombinant antigen adjusted to 2 g/ml of protein in 3 M urea buffer (3 M urea,
100 mM NaH2PO4, 10 mM Tris base, pH 8.2). Blank control wells were coated
with 0.01% BSA in 3 M urea buffer. The plates were washed in PBS with 0.5%
Tween 20 (PBST) and then blocked with 1% BSA in PBST for 2 h at 37°C. After
another washing, plasma diluted in 0.1% BSA in PBST (Table 2) was added (50
l per well), and the plates were incubated for 2 h at 37°C. The plates were
washed again, and then either streptavidin-HRP-conjugated polyclonal rabbit
anti-human antibody (IgA and IgM; Dako, Camberfield, Australia) or unlabeled
polyclonal rabbit anti-human antibody (IgG and IgE; Dako, Australia) in 0.1%
BSA in PBST was added (50 l per well). The plates were incubated for 2 h at
37°C. For IgG and IgE detection, the plates were washed again and incubated
with HRP-conjugated goat anti-rabbit IgG (50 l per well; Promega, Sydney,
Australia) for a further 2 h at 37°C. All plates were given a final wash with PBST
and PBS before the addition of a solution of 5 mg O-phenylenediamine dihy-
drochloride (Sigma, Australia) in phosphate citrate buffer with sodium perborate
(50 l per well). The plates were incubated for 10 min at 37°C, according to the
manufacturer’s instructions. Color development was stopped with 4 M HCl (50
l per well), and absorbance was measured at 490 nm. Background (no-antigen)-
corrected absorbance of replicate wells was determined, and the data are pre-
sented as the mean optical density at 490 nm (OD490) standard deviation (SD).
The IgE positive cutoff value was determined as 3 SD above the mean absor-
bance for a panel of 7 N plasmas.
Levels of Der p 1-specific IgE were determined by dissociation enhanced
lanthanide fluoroimmunoassays (DELFIA) (Wallac, Turku, Finland). Total IgE
was determined by ImmunoCap assay (Pharmacia Diagnostics AB, Uppsala,
Sweden).
IgE cross-reactivity studies. To investigate the cross-reactivity of IgE with SM
and HDM allergens, the ability of whole HDM extract to inhibit IgE immuno-
reactivity with S. scabiei Ssag1.2 and CO8 was tested by inhibition ELISA (42).
Briefly, ELISA plates were coated with Ssag1.2 (2 g/ml in 3 M urea buffer; 50
l per well) or CO8 (1 g/ml in 1 M urea buffer; 50 l per well) and incubated
overnight at 4°C. The plates were washed and blocked as described above.
Plasma samples were diluted 1:160 (Ssag 1.2) or 1:80 (CO8) in 0.1% BSA in
PBST. The diluted plasmas were preincubated with increasing concentrations of
HDM extract or, as positive and negative controls, Ssag 1.2 or CO8 or no
inhibitor, for 90 min at room temperature. The plasma and HDM extract mix-
tures or diluted plasma samples were added to the coated plates, and the IgE
ELISA protocol was followed as described above. The percentage of inhibition
of IgE binding was calculated as follows: percent inhibition  100  (OD490 of
plasma with HDM extract/OD490 of plasma without HDM extract  100).
PBMC proliferation studies. PBMC were cultured in triplicate (1  105
cells/200 l/well) in 96-well plates (Nunc Maxisorp) in complete medium (RPMI
1640 supplemented with 100 IU/ml penicillin or streptomycin, 2 mol/liter L-
glutamine [Gibco Life Technologies, Auckland, NZ], and 5% screened heat-
inactivated human AB serum [Sigma, St. Louis, MO]). The PBMC were stim-
ulated with recombinant SM antigen at concentrations predetermined to induce
maximum proliferation (1 g for CO8 and FO4, 10 g for GO8, and 3 g for
Ssag) for 7 days at 37°C in 5% CO2. Control wells contained no antigen or
phytohemagglutinin (final concentration, 2.5 g/ml). After 6 days, the cells were
pulsed with [3H]thymidine (1 Ci/well; Amersham, Pharmacia, GE Healthcare
Pty Ltd., NSW, Australia) overnight and then harvested. CPM were determined
with a Wallac Winspectral Liquid Scintillation Counter (Perkin Elmer, Victoria,
Australia). The results are presented as the mean stimulation index (SI) of
triplicates, where the SI is equal to CPM challenged cells/non-CPM-challenged
cells. An SI of 5 was considered a positive response.
Cytokine analysis. Supernatants (20 l per well) were collected from day 3 and
day 6 cultures of fresh PBMC stimulated with S. scabiei cysteine protease CO8
and apolipoprotein Ssag1.2. Triplicate samples were pooled and stored at 80°C
until analysis was done. The supernatants were analyzed for levels of interleukin
2 (IL-2), IL-4, IL-5, IL-10, tumor necrosis factor (TNF), and gamma interferon
(IFN-	) with the Cytometric Bead Array (CBA) Human Th1/Th2 Cytokine Kit
(Becton Dickinson, NSW, Australia) and a four-color FACSCalibur flow cytom-
eter (Becton Dickinson, CA), according to the manufacturer’s instructions. Lev-
els of IL-13 were tested with the Human IL-13 CBA Flex Set (Becton Dickinson,
Australia). After fluorescence data were obtained, the results were generated in
data format with the BD CBA software.
TABLE 2. Antibody dilutions for detection of antibodies to recombinant scabies antigens in human plasma samples by ELISA
Antibody type
Dilution
CO8 FO4 GO3 Ssag1.2
First Second Third First Second Third First Second Third First Second Third
IgE 100 500 500 100 500 500 50 1,000 1,000 100 4,000 4,000
IgM 100 2,000 NAa 100 4,000 NA NA NA NA 50 1,000 NA
IgA 100 2,000 NA 90 1,000 NA NA NA NA 50 500 NA
IgG 2,000 8,000 8,000 NA NA NA NA NA NA 200 1,000 NA
IgG4 2,000 1,000 1,000 NA NA NA 50 500 1,000 10 1,000 2,000
IgG1 160 500 1,000 NA NA NA NA NA NA 100 1,000 2,000
a NA, not applicable.
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Statistical analysis. Differences between the distributions of 2 unmatched
groups were analyzed with nonparametric Mann-Whitney U tests, using Graph-
Pad PRISM version 5.0 (GraphPad Software, Inc.). The nonparametric Kruskal-
Wallis test was used to assess differences between 3 or more groups. Differences
were considered statistically significant when the P value was 0.05.
RESULTS
Expression, purification, and localization of recombinant S.
scabiei proteins. The expressed, purified SM recombinant pro-
teins migrated with molecular masses between 25 and 46 kDa
(Fig. 1A). The Ssag1.2 protein migrated as 2 or 3 multiple
bands due to the formation of aggregates on refolding under
denaturing conditions, as observed previously for this protein
(25). Western blotting demonstrated that the sample from the
subject with CS showed strong IgE binding to CO8 and Ssag1.2
and weaker binding to FO4 and GO3 (Fig. 1B).
Immunolocalization studies using mouse anti-CO8 and rab-
bit anti-Ssag1.2 antisera and sections of human skin infested
with mites clearly demonstrated the localization of Ssag1.2 as
a component of the external cuticle and CO8 within the gas-
trointestinal tracts of the mites (Fig. 2). The CO8 was also
localized to the scybala (fecal pellets; data not shown). Sections
probed with polyclonal anti-human IgE antibodies showed IgE
inundating the mite burrow (Fig. 2E) or localized inside the
gastrointestinal tract of the mite (Fig. 2F).
Characterization of human humoral immune response to S.
scabiei cysteine proteases and apolipoprotein and evaluation
of cross-reactivity with HDM allergens. Total IgE levels (kU/
liter) for subjects with CS were significantly higher than the
levels observed for subjects with OS (P  0.0364; data not
shown). Furthermore, IgE binding to the purified recombinant
mite proteins C08, F04, and Ssag1.2 was stronger for subjects
with CS than for subjects with OS (P 0.0037, P 0.0019, and
P  0.0062, respectively) and for control (N) subjects (P 
0.0004, P  0.0004, and P  0.0005, respectively) (Fig. 3). No
significant IgE binding of plasma from subjects with CS to
GO3, the serine protease construct, was observed (Fig. 3).
Compared to naive subjects, significant IgE binding of plasma
from subjects with OS to CO8 (P  0.0047) and Ssag1.2 (P 
0.0003) was also observed. However, significant binding to the
inactive form of the cysteine protease molecule (F04) or the
serine protease (GO3) molecule was not observed. Compared
with the cysteine (CO8; P  0.0279) and serine (GO3; P 
0.0039) protease constructs, the apolipoprotein fragment
Ssag1.2 was more highly recognized by IgE from subjects with
CS than by that from subjects with OS. An IgE reactivity
threshold was determined for CO8 and Ssag1.2 by calculating
the mean of the naive group plus 3 standard deviations for
each protein. Based on these results, the sensitivity of the IgE
ELISA for determining scabies infestation was 88% and the
specificity was 100%, using the Ssag1.2 fragment. Similarly, the
sensitivity was 76% and the specificity was 100% using CO8.
Subjects with CS showed significantly increased IgG4 bind-
ing to C08 (P  0.0104), F04 (P  0.0044), GO3 (P  0.0003),
and Ssag1.2 (P  0.0001) than did naïve subjects but only
significantly increased IgG4 binding to Ssag1.2 (P  0.0343)
compared to subjects with OS (Fig. 3). Plasma from subjects
with OS also showed increased binding levels of IgG4 to CO8
(P  0.0104), GO3 (P  0.0003), and Ssag1.2 (P  0.0012)
compared with naïve subjects.
Interestingly, increased binding of IgA to CO8 was observed
for both the CS (P  0.0003) and OS (P  0.0002) groups, and
to Ssag1.2 for the CS group (P  0.0012), compared with the
control (N) group (Fig. 3). Comparison of binding levels for
IgG, IgG1, and IgM ELISA data between groups or proteins
was not informative.
To investigate the cross-reactivity of SM proteins with HDM
proteins, plasma from 7 N-HDM subjects was tested for IgE
reactivity against the S. scabiei Ssag1.2 construct. No IgE bind-
ing was observed (data not shown). In addition, IgE binding of
plasma from subjects with CS or OS to the recombinant HDM
group 1 allergen Der p 1 was also tested, but no binding was
observed (data not shown).
The ability of whole HDM extract to inhibit IgE immuno-
reactivity with S. scabiei CO8 and Ssag1.2 was tested in inhi-
bition ELISA (Fig. 4A and B). The maximum percent inhibi-
tion by HDM extract of scabies subject plasma IgE binding to
CO8 was 30% and to Ssag1.2 was 17% (25 g/ml and 20 g/ml
of HDM extract as the inhibitor, respectively).
Characterization of the human cellular response to S. sca-
biei proteases and apolipoprotein. One subject allocated to the
OS group had excessively elevated SI values for all 4 SM
recombinant proteins (CO8, 155.52; FO4, 137.65; GO3, 97.68;
Ssag1.2, 71.11), in combination with a proliferative response to
phytohemagglutinin within the normal range (data not shown).
As the SI values far exceeded even those observed for subjects
with CS, these data were excluded from the analysis.
The overall percentage of subjects showing positive prolif-
erative responses to scabies recombinant antigens CO8, FO4,
GO3, and Ssag1.2 was significantly higher in S. scabiei-infected
individuals than in non-S. scabiei-infected individuals (P 
0.03). No significant differences in percentages of positive sub-
jects were observed for the CS group compared with the OS
group (Fig. 5A), although there was a trend toward higher
FIG. 1. Purified S. scabiei var. hominis recombinant antigens
Ssag1.2, GST, CO8, FO4, and GO3. (A) SDS-12% PAGE stained with
Coomassie brilliant blue. (B) Western blot with plasma from a subject
with crusted scabies.
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reactivity to the FO4, GO3, and Ssag1.2 antigens in the CS
group.
The PBMC proliferative responses to the 4 SM recombinant
antigens varied in the 4 subject groups (Fig. 5B). The responses
to all antigens were significantly higher in the CS group than in
the N group (CO8, P  0.0037; FO4, P  0.0073; GO3, P 
0.0128; Ssag1.2, P  0.0264). However, no significant differ-
ences in responses to any antigens were observed when the CS
and OS groups, the OS and N groups, or the OS and N-HDM
groups were compared. Additionally, there were no significant
differences between stimulatory responses to the 4 recombi-
nant antigens within the CS group. However, significant dif-
ferences were observed between the 4 subject groups in reac-
tivity with CO8 (P  0.0084) and GO3 (P  0.0195), but not
with FO4 (P  0.0514) or Ssag1.2 (P  0.0811).
The cellular immune response to SM antigens was also char-
acterized by evaluating IFN-	, IL-4, IL-5, IL-10, TNF, IL-2,
and IL-13 cytokine profiles in PBMC culture supernatants
collected after 72 h of CO8 or Ssag1.2 stimulation. A clear
trend of decreased IFN-	 production was observed in CO8-
and Ssag1.2-stimulated PBMC from subjects with CS com-
pared to subjects with OS (Fig. 6A and B). However, signifi-
cant differences between IFN-	 levels were observed only in
the OS and N groups for the CO8-stimulated PBMC (P 
0.0480). No differences in IL-4 levels were observed between
groups for either stimulation protein, but the IFN-	/IL-4 ratio
for CO8 stimulation trended lower in the CS group than in the
OS group (P  0.0734) (data not shown). A trend of increased
IL-5 expression was also observed in subjects with CS, with 3 of
7 subjects secreting high levels of IL-5 cytokine in response to
FIG. 2. Sections of human skin infested with S. scabiei mites probed with rabbit anti-Ssag1.2, showing staining of mite external cuticle (A);
probed with rabbit prebleed (B); probed with mouse anti-CO8, showing staining of the mite gastrointestinal tract (C); probed with mouse prebleed
(D); and probed with anti-human IgE showing in vivo localization of IgE in the mite gastrointestinal tract and burrow (E and F). (m, mouthparts;
c, cuticle; g, gut; b, burrow).
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CO8 stimulation. However, significant differences between
IL-5 levels were observed only between the CS and N groups
(P  0.0286). The levels of IL-10 cytokine were significantly
higher in CO8-stimulated PBMC from the N group than in
those from the CS group (P  0.0480), and the OS group
showed a trend toward a decreased level when similarly com-
pared (P  0.0732). No differences in TNF and IL-2 levels
were observed between any groups for either SM protein. The
IL-13 levels in PBMC supernatants at 48 h after stimulation
with CO8 were significantly increased in the CS group com-
pared to the N group (P  0.0317) (Fig. 6C). However, there
were no significant differences between IL-13 levels in the CS
and OS groups or the OS and N groups.
DISCUSSION
Scabies mite proteins have considerable similarity to the
extensively studied HDM proteins that are a major cause of
allergic disease. The cloning of SM proteins corresponding to
those of the predominant HDM allergens has now facilitated
studies of their sequence homology (25, 26, 34, 45, 46, 49, 50),
localization (47, 51), enzymatic activity (7, 16, 22, 35, 40), and
interactions with the immune system (8, 11, 30). Here, we have
studied differences in the types and magnitudes of the systemic
FIG. 3. Specific anti-CO8, -FO4, -GO3, and -Ssag1.2 plasma antibody levels measured by ELISA in subjects with CS and OS and naïve
(N) subjects. The bars represent the median with interquartile range. a, significantly different (P  0.05) from OS and N groups; b, significantly
different (P  0.05) from the N group only. Specific P values are given in the text.
FIG. 4. (A) Inhibition ELISA by HDM extract for plasma IgE from
a subject with CS. CO8 was immobilized on an ELISA plate, and the
inhibition of CS IgE binding by increasing concentrations of HDM
extract or CO8 as a positive control was assessed. (B) Same as for
panel A, with apolipoprotein Ssag1.2 immobilized on the plate and as
the positive control.
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antibody and cellular responses to characterize the specific
immune response in OS and compare it to the more severe and
debilitating crusted form of the disease (CS). Our studies also
looked for any cross-reactivity between SM and HDM proteins
to assess the potential future design of specific immunodiag-
nostics for scabies infestation. Our results demonstrate that
patients with OS and CS have a specific allergic IgE response
to S. scabiei cysteine proteases and apolipoprotein. Clinical
severity was reflected in differences in the types and magni-
tudes of the antibody and cellular responses to these proteins.
Furthermore, our results show that a nonprotective Th2 re-
sponse occurs in patients with CS, which may, in part, account
for the pathology of this disease form.
In Darwin, patients with CS have extremely high levels of
total IgE in serum (41). In this study, subjects with CS dem-
onstrated significantly higher levels of total IgE (data not
shown) and scabies-specific IgE and IgG4 than subjects with
OS and naïve control subjects. A correlation was observed
between levels of CO8- and Ssag1.2-specific IgE and IgG4
antibody responses and the classification of subjects into dis-
ease types in conjunction with observed inflammatory pro-
cesses. These results demonstrate that Ssag1.2 and CO8 are
present in scabies infestations at sufficient levels to elicit the
production of scabies-specific IgE and IgG4 and are consistent
with the conclusion that they are abundant allergens. Previous
studies revealed that sequences corresponding to an apoli-
poprotein are the third most frequent cDNA clones in an S.
scabiei EST library (21), with the abundance of the group 1
scabies allergen cDNA 10 times lower (27). These frequencies
may account for the greater immunological response to
Ssag1.2 compared with the other proteins in our study.
In this study, levels of specific IgG, IgG1, and IgM were not
informative for disease status. Increased levels of total IgG and
IgM have previously been observed in subjects with OS. How-
ever, it is unclear whether these increased antibody levels rep-
resent specific or nonspecific immunological reactions against
scabies antigens or a response to the secondary cutaneous
bacterial infections commonly associated with scabies (14).
Synthesis of IgG4 is related to the Th2 immune response, in
combination with chronic or repeated antigenic exposure, and
may be of particular benefit to the host in protection against
anaphylactic responses by blocking IgE receptor sites on anti-
gens. Protective mechanisms may also be modulated by the
IgE/IgG4 ratio, which tends to be high in heavy infections of
schistosomiasis and lymphatic filariasis (1, 32). A correlation
between IgE responses and protective immunity has been es-
tablished in human schistosomiasis (23, 24, 39). The reasons
for the extreme nonprotective IgE and IgG4 scabies-specific
antibody responses and the eosinophilia seen in subjects with
CS remain unknown and appear to be related to an inappro-
priate Th2-polarized immune response. Future studies need to
determine the roles of mast cells, basophils, and eosinophils in
CS and how levels of specific IgE and IgG4 are regulated in
CS. Additionally, investigating the clinical effect of selectively
boosting IgG4 over IgE is important. Finally, understanding
the immunoregulatory mechanism involved in the protective
immune response in OS is also necessary to develop rational
strategies for intervention. This understanding is especially
important when a Th2 response is associated with disease
susceptibility.
Secretory IgA is important in local (mucosal) immunity and
is the predominant antibody in external secretions, such as
sweat, saliva, and tears, as well as in intestinal and respiratory
secretions, after stimulation. Total serum IgA levels have been
reported to be significantly lower during OS infestation than
following successful treatment (19, 38). However, in this study,
specific IgA binding levels to the SM recombinant construct
CO8 were significantly increased in both the CS and OS groups
compared to the control (N) group. The observation that
mouse anti-CO8 polyclonal antibody predominantly bound to
the gastrointestinal tracts of the mites suggests that S. scabiei
cysteine proteases play a role in skin digestion and mite bur-
rowing and that specific anti-CO8 IgA is also involved in the
skin immune response.
Our studies demonstrated minimal cross-reactivity between
IgE from HDM-allergic individuals (N-HDM) and the S. sca-
biei allergens CO8 and Ssag1.2. Similarly, plasma from subjects
with scabies demonstrated little or no IgE cross-reactivity with
purified Der p 1 allergens. S. scabiei proteins that fail to show
cross-reactivity with HDM proteins, but which are recognized
FIG. 5. (A) Percentage of subjects showing positive responses
(stimulation index  5) after culture of PBMCs stimulated with S.
scabiei recombinant proteins CO8, FO4, Ssag1.2, and GO3. All CS and
OS group results were significantly different (P  0.05) from those of
the N group. (B) Mean SI (with 95% confidence interval) after culture
of PBMC stimulated with S. scabiei recombinant proteins CO8, FO4,
Ssag1.2, and GO3. *, significantly different (P  0.05) from the N
group for each protein. Specific P values are given in the text. CS, n 
15; OS, n  12; N, n  12; N-HDM, n  5.
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by serum antibody from scabies-infested subjects, provide po-
tential target antigens for subsequent development into a high-
performance serodiagnostic test for scabies infestation.
Regulation of the immune response directed against S. sca-
biei is critical to establish effective control of the disease. To
gain a better understanding of the possible roles that T cells
and their associated cytokines have in the disease progression
and the protective immune responses to infection, a detailed
study of the antigen-specific, cytokine-producing T cells was
performed. The S. scabiei recombinant proteins CO8, FO4,
A
FIG. 6. (A) Secreted IFN-	, TNF, IL-10, IL-5, IL-4, and IL-2 cytokine levels analyzed at 72 h from CO8-stimulated PBMCs. CS, n  7; OS,
n  7; N, n  5. Note that one N value (IL-10) is outside the graph limits (797 pg/ml). (B) Secreted IFN-	, TNF, IL-10, IL-5, IL-4, and IL-2
cytokine levels analyzed at 72 h from Ssag1.2-stimulated PBMCs. CS, n  6; OS, n  7; N, n  5. (C) Secreted IL-13 cytokine levels analyzed at
48 h from CO8-stimulated PBMCs. CS, n  5; OS, n  5; N, n  5. The bars represent box and whiskers displaying minima and maxima. *,
significantly different (P  0.05) from the N group. Specific P values are given in the text. Horizontal lines within the bars indicate medians.
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and Ssag1.2 induced strong proliferative responses of PBMC
from scabies subjects compared to control subjects. Subjects
with OS tended to show less stimulation than subjects with CS.
These results demonstrate the importance of the cell-mediated
immune response to S. scabiei, with all antigens inducing a
stimulatory response in PBMC from scabies-exposed subjects.
Of note, the subject classified as OS who was excluded from
the cell proliferation analysis due to extremely high responses
FIG. 6—Continued.
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to scabies antigens was a 48-year-old man who had been ad-
mitted 3 times to the hospital for suspected crusted scabies (in
2002, 2005, and 2006). However, mites were found in skin
scrapings only on the second admission (only 4 mites were
observed). The blood used in the assay was taken on the 2006
admission, in which crusting on the subject’s feet was docu-
mented, but no mites were observed in multiple skin scrapings.
To maintain consistency in the study and based on our criteria
of subjects with CS having more than 5 mites in skin scrapings,
he was placed in the OS group. This situation highlights the
difficulties faced by clinicians in diagnosing suspected CS and
the need for more robust diagnostic tests.
The role of T cells secreting Th2-type cytokines in asthma
and allergic diseases has been well documented (28). The cys-
teine and serine proteases of the dust mite; the serine protease
of Aspergillus fumigatus; the aspartic protease of the cockroach,
Bla g 2; and helminth proteases have all been documented to
induce Th2-driven inflammatory responses dominated by ele-
vated IgE, eosinophilia, and Th2 cells (15). Therefore, the
present study analyzed for cytokines that might be involved in
the activation of an effective anti-Sarcoptes immune response.
Our sample sizes were small, and thus, the nonparametric tests
used for analysis had less power or were less likely to detect
true differences between groups. Nevertheless, the in vitro re-
sponses of cytokines to S. scabiei antigens observed in cultures
confirmed the in vivo immune modulation to scabies infesta-
tion and the antibody class switches detected in plasma sam-
ples. In subjects with CS versus those with OS, trends toward
increased levels of IL-5 and IL-13, in combination with lower
levels of IFN-	, were observed in the supernatants of CO8-
stimulated PBMC. These findings are similar to those seen
with Der p 1 and HDM allergy. Importantly, the proteolytic
activity of HDM cysteine proteases is now believed to play a
significant role in its ability to elicit Th2 responses (12). In this
study, the recombinant SM cysteine and serine proteases were
not expressed as active protease enzymes. However, CO8 is
clearly recognized as a major allergen. The Th2 cytokines IL-4
and IL-13 play important roles in the class switching of B cells
to an IgE-secreting phenotype and in the generation of Th2-
type immune responses. The cytokine IL-5 promotes the mat-
uration of eosinophils, and eosinophils are known to be ex-
tremely high in CS (42). Interestingly, in this analysis, no
significant differences in IL-4 levels could be demonstrated
between subjects with CS and those with OS. However, the
IFN-	/IL-4 ratio indicated a trend toward a Th2 response in
CS and a Th1 response in OS (P  0.07). Statistically signifi-
cantly elevated levels of IL-4 have been reported previously in
pilot studies on cytokine production in fresh PBMC collected
from subjects with CS and from noninfested control subjects in
northern Australia (50). In this study, the subjects with CS
were at different stages of disease progression. Therefore, it is
possible that greater differences in PBMC-secreted levels
would be revealed by a detailed time course analysis of IL-4
production in CS. The in vivo findings of significantly increased
levels of scabies-specific IgE and IgG4 in plasma from subjects
with CS and documented clinical eosinophilia in CS are col-
lectively indicative of the trend toward increased production of
the cytokines IL-4, IL-5, and IL-13 in CS subjects.
Notably, CO8-stimulated PBMC from control (N) subjects
showed significantly increased levels of IL-10, similar to pre-
vious studies using whole SM extract (3). The cytokine IL-10 is
capable of inhibiting synthesis of the proinflammatory cyto-
kines IFN-	, IL-2, and TNF and is also stimulatory toward
certain T cells and mast cells and stimulates B-cell maturation
and antibody production. These results suggest IL-10 may play
a role in the human delayed immune response, depressing the
inflammatory and allergic responses so that clinical symptoms
are not seen until 4 to 6 weeks after a person becomes infested
with scabies mites.
In summary, patients with OS and CS have a specific allergic
IgE response to S. scabiei cysteine proteases and apolipopro-
tein. Clinical severity is reflected in differences in the types and
magnitudes of the antibody and cellular responses to these
proteins. Our results demonstrate a nonprotective Th-2 re-
sponse in patients with CS, as previously hypothesized (50),
and suggest that dysfunctional effector cells may, in part, ac-
count for the pathology of CS. Difficulties associated with the
collection and culture of S. scabiei var. hominis have previously
confounded studies on the characterization of the immune
responses in scabies. These studies using recombinant proteins
are the first to describe the specific immune response in sca-
bies. This information will assist in developing tools for the
early diagnosis of scabies carriers and in better control of the
infestation in communities where the disease is endemic. This
research considerably advances our understanding of the im-
munopathogenesis of scabies and helps direct future develop-
ment of specific immunotherapy and vaccines.
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